UK faces gene editing crossroads as EU adopts NGT rules

The European Parliament’s formal adoption of new genomic techniques (NGTs) rules on June 16 marks a turning point in EU policy on gene editing, with full implementation expected within two years.

But for the UK, the move poses a deeper strategic question: should it continue to diverge from the EU to gain a first‑mover advantage, or work towards a harmonised regulatory framework?

The UK – or more accurately England – has already moved ahead with the Genetic Technology (Precision Breeding) Act (2023), creating a pathway for gene‑edited crops and positioning itself as potentially one of the most permissive markets in Europe.

Support for the UK’s more agile approach is strong across parts of the sector.

Case for divergence: speed, flexibility and first-mover advantage

The NFU has described the framework as a “very significant and positive development,” highlighting expectations that gene editing could unlock productivity gains and new crop traits.

Speaking to AgNavigator, biologist Dr Julian Little said the government has signalled its intent to maintain that divergence:

“The current government has made it clear that they are looking for an exception when it comes to alignment with Europe with this particular thing.”

For proponents, the UK system is structurally more flexible. While both the UK and EU allow techniques such as targeted mutagenesis and cisgenesis, Brussels has imposed tighter parameters – such as limits on the number of edits per plant and exclusions for certain traits.

Little argues this makes the EU framework less adaptable over time.

“The UK setup is future‑proofed, whereas the European system is more of a snapshot in time,” he said.

With EU rules unlikely to be fully operational until around 2028, supporters see a window for the UK to attract innovation and investment – provided it can move quickly.

But first-mover advantage not yet realised

That opportunity, however, remains largely theoretical.

Despite the regulatory framework being in place, precision-bred crops are still not commercially available in England. Key elements of implementation – particularly the national listing of precision-bred seeds – have yet to be finalised.

Until this system is in place, farmers cannot grow gene-edited crops commercially, even though consumers can technically buy products derived from them.

“There is one area the UK needs to sort out quite quickly… otherwise we can’t actually sell precision-bred seed,” Little said.

The delay raises concerns that the UK’s early lead could be eroded before it translates into real-world adoption.

Alignment argument: trade, certainty and scale

At the same time, a counterargument exists among those focused on market access and trade.

A cross-party report from the UK Trade and Business Commission (UKTBC) has called for the UK to pause further divergence and instead work towards a harmonised UK‑EU framework as part of a broader sanitary and phyto-sanitary (SPS) agreement.

The case is economic: alignment could reduce trade barriers, improve food security and boost business confidence across integrated supply chains.

For a sector deeply entwined with European markets, regulatory divergence risks introducing friction just as the UK seeks closer economic ties with the bloc.

A third path: convergence – on UK terms

Between these two positions, a hybrid view is emerging within the biotech sector.

Some leaders are calling not for UK alignment with the EU, but for the EU to move closer to the UK’s more permissive model.

Ross Hendron, CEO & co-founder of Wild Bioscience, a start-up using precision breeding techniques to make more resilient crops, argued for a shared, science-led approach:

“We would hope to see continued convergence on a science-led, outcome-based approach that is live in England today,” he told AgNavigator. “The goal should be that we’re all speaking the same language and collaborating on solutions that can rapidly scale.”

He pointed out that Britain and the EU share “the fastest-warming continent on Earth”, highlighted during the historic heatwave last week. The future of food security will therefore “require access to leading technologies that address the scale of this challenge”.

The BioIndustry Association (BIA) has echoed this stance, welcoming the EU’s reforms but suggesting they still fall short of a truly innovation‑friendly framework. It has urged policymakers to ensure any future alignment supports both trade and commercialisation, while preserving the UK’s regulatory agility in the near term.

“With the NGT rules still a while away from being implemented, it is important the UK secures a carve-out and maintains its own PBO Act.” Linda Bedenik, the BIA’s head of bio solutions and international policy, told us.

She added: “We remain open to future alignment on to the regulation of gene editing in the long-term, where it ensures a harmonised, pro-innovation approach that enables trade and supports biotech innovation.”

Divergence vs alignment: a defining policy choice

The debate now facing policymakers is not simply technical – it is strategic. Divergence offers speed, flexibility and the potential to lead. Alignment offers scale, certainty and trade integration. Convergence (on UK terms) offers a third, more ambitious route.

Each carries risks. Push too far ahead, and the UK may create barriers with its largest trading partner. Move too close to EU rules, and it may lose its early mover advantage.

What comes next

The coming months will be critical.

If the UK can operationalise its framework – finalising seed listing and enabling commercial rollout – it may yet establish itself as a European hub for gene editing innovation.

But as the EU closes the gap with its own NGT regime, the space for differentiation is narrowing.